|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2001-11-5
|
|
pubmed:abstractText |
The Epirubicin (EPI) and ifosfamide (IFO) combination has been widely tested in soft tissue sarcomas, even though the optimal schedule of drug administration has still to be defined. In this article, we reviewed the activity and the toxicity of two EPI- and IFO-based schedules in newly diagnosed sarcomas.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0378-584X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2001 S. Karger GmbH, Freiburg
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
465-8
|
|
pubmed:dateRevised |
2010-3-23
|
|
pubmed:meshHeading |
pubmed-meshheading:11694773-Adolescent,
pubmed-meshheading:11694773-Adult,
pubmed-meshheading:11694773-Aged,
pubmed-meshheading:11694773-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11694773-Dose-Response Relationship, Drug,
pubmed-meshheading:11694773-Drug Administration Schedule,
pubmed-meshheading:11694773-Epirubicin,
pubmed-meshheading:11694773-Female,
pubmed-meshheading:11694773-Humans,
pubmed-meshheading:11694773-Ifosfamide,
pubmed-meshheading:11694773-Male,
pubmed-meshheading:11694773-Middle Aged,
pubmed-meshheading:11694773-Neoplasm Staging,
pubmed-meshheading:11694773-Sarcoma,
pubmed-meshheading:11694773-Soft Tissue Neoplasms,
pubmed-meshheading:11694773-Survival Rate
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules.
|
|
pubmed:affiliation |
Regina Elena Institute for Cancer Research and Treatment, Division of Medical Oncology A, S. Raffaele Hospital, Rome, Italy. lserrone@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
